Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
About three months before that, Novo Nordisk in February linked up with California’s Neomorph in its own $1.46 billion accord to discover, develop and commercialize glue degraders against a ...
Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, Biogen Inc. and Neomorph Inc., are moving forward in the same space in a ...
(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...
As part of the collaboration, the companies aim to utilize Neomorph’s proprietary molecular glue discovery platform to accelerate the identification and validation of novel small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback